Agenus (NASDAQ:AGEN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Agenus (NASDAQ:AGEN) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

Several other research firms also recently issued reports on AGEN. HC Wainwright raised their price target on shares of Agenus from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Finally, Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.

Agenus Trading Down 0.8%

NASDAQ:AGEN opened at $4.97 on Friday. The stock’s 50-day moving average is $3.48 and its 200-day moving average is $3.50. Agenus has a 1-year low of $2.71 and a 1-year high of $8.70. The stock has a market cap of $206.95 million, a P/E ratio of 3.13 and a beta of 1.55.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. The business had revenue of $33.74 million during the quarter, compared to the consensus estimate of $129.50 million. As a group, equities analysts forecast that Agenus will post 0.83 EPS for the current year.

Institutional Investors Weigh In On Agenus

Large investors have recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new position in Agenus in the fourth quarter valued at $31,000. R Squared Ltd acquired a new stake in Agenus during the 4th quarter worth about $41,000. Redwood Family Wealth LLC bought a new position in shares of Agenus in the 4th quarter worth about $44,000. Quadrature Capital Ltd bought a new position in shares of Agenus in the 4th quarter worth about $54,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Agenus in the 3rd quarter valued at about $54,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.